Back to search results

Growth Hormone for Gastroparesis Study

This study is looking into whether a growth hormone called somapacitan-beco (Sogroya®) can help improve symptoms for people with gastroparesis (a condition where your stomach empties food too slowly). You might be able to join if you are between 18 and 65 years old, have had gastroparesis symptoms for over six months that haven't improved with standard treatments, and have a Gastroparesis Cardinal Symptom Index (GCSI) score above 21. The study aims to see if this treatment leads to better symptom scores. This study is currently unclear about its recruitment status and plans to enroll 10 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 10 participants.
What's involved
Participants will receive somapacitan-beco (Sogroya®) as a subcutaneous injection once weekly for 12 weeks. Symptoms will be measured at baseline, 4, 8, 12, and 14 weeks.
Compensation
Not stated in the trial record.
Follow-up
Symptoms are measured up to 14 weeks, which is two weeks after the last treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06803589

Growth Hormone for the Treatment of Gastroparesis

Recruiting
EARLY_PHASE1Ages 18–65InterventionalTreatment
Mayo Clinic
~10 participants
Updated 2026-04-16 on ClinicalTrials.gov
What's tested:Growth Hormone

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Gastroparesis Cardinal Symptom Index (GCSI)
Measured over Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks

Conditions

Gastroparesis

Explore related trials

Gastroparesis

Where it's being run

2 sites across 1 states
Arizona2

Study leadership

  • Tisha Lunsford · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Guillermo GI Program Coordinator, Research
[email protected]
480-301-4679
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Symptoms \> 6 months that have not responded satisfactorily to standard treatment.
For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21

Exclusion

Known history of GH deficiency, hypothalamic or pituitary disease
Diabetes
Prior use of GH therapy
Age-adjusted low serum IGF1
Women on oral estrogen therapy6
Pregnancy or nursing
History of malignant solid tumors
Obesity (BMI \> 30)History of coronary and thromboembolic diseases.
History of sarcoidosis
History of pituitary surgery
History of thyroid nodules.
Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
Failure to give informed consent.

What this trial measures

  • Gastroparesis Cardinal Symptom Index (GCSI)Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks

    The Gastroparesis Cardinal Symptom Index (GCSI) is a questionnaire that assesses the severity of gastroparesis symptoms of: nausea, early satiety, postprandial fullness, and upper abdominal pain. Scores range from 0-none to 4-very severe.